[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Mitigation](https://github.com/mm80843/T3.5/tree/main/docs/Mitigation/index.md) >> Individual ID:PBN__Mitigation_1186 

# __Evaluate efficacy differences based on symptoms__

## Category to which it belongs

* [Implementation of various strategies to improve healthcare infrastructure, disease management, waste disposal, symptom recognition, and treatment through advanced technology and interventions.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_61.md)

## Closest similar item

* [Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2513.md)
* [Evaluation of symptoms](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_4532.md)
* [Symptom screening](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_3438.md)
* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_1594.md)
* [Implement regular and widespread symptom monitoring and testing, both symptomatic and asymptomatic](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2036.md)
* [Identify missing information and develop logical relations linking drugs, coronaviruses, and conditions for drug efficacy.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_1963.md)
* [Improve testing frequency and accuracy, conduct seroprevalence surveys.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2511.md)
* [Self-reported symptoms](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_3260.md)
* [Combine direct measurements with numerical simulations to inform decision-making, conduct rigorous study on intervention effectiveness](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2007.md)
* [Behavioral interventions](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_3571.md)

## Benefits linked to a risk

* [Tailored protection for symptomatic and asymptomatic patients](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1185.md)

## Risks possibly mitigated by this Mitigation

* [Variability in disease severity in reinfected patients](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_863.md)

